Tirzepatide Preparation and Purification

Significance of the topic

Tirzepatide is a dual-action incretin-related peptide with strong therapeutic potential for type 2 diabetes and obesity management due to its combined GLP-1 receptor agonism and additional metabolic benefits. Reliable preparative and analytical workflows for isolating and characterizing tirzepatide from crude synthetic mixtures are critical for medicinal chemistry, process development, and quality control in both research and preclinical production settings.

Objectives and study overview

This application note describes a practical workflow for preparative HPLC purification of crude tirzepatide and subsequent analytical confirmation of fraction purity. The primary aims were to: 1) develop a preparative separation using a Luna 10 µm PREP C18(3) column on an Octopus Plus preparative HPLC system; 2) collect fractions and assess purity using an Agilent 1100 system with a Luna 5 µm C18(2) analytical column; and 3) demonstrate method suitability for separating the target peptide from related impurities present in a customer-supplied crude sample.

Methodology

• Sample preparation: 120 mg of crude tirzepatide dissolved in DMSO then diluted with a 1:1 water:acetonitrile mixture prior to injection for preparative runs.
• Preparative chromatography: reversed-phase C18 stationary phase (Luna 10 µm PREP C18(3), 250 x 10 mm) with an ammonium acetate-containing aqueous phase and an organic phase composed of acetonitrile blended with ammonium acetate solution. Isocratic/gradient conditions were applied at a 5.0 mL/min flow rate with 10 mL injection volumes; UV detection at 220 nm was used for fraction collection.
• Analytical confirmation: Luna 5 µm C18(2) column (250 x 4.6 mm) with 0.1% trifluoroacetic acid (TFA) in water and in acetonitrile as mobile phases, 1.0 mL/min flow, 30 °C column temperature, 30 µL injections and UV detection at 220 nm. Collected preparative fractions were re-injected to confirm purity and to profile impurity peaks and their relative areas.

Instrumentation used

• Octopus Plus preparative HPLC system (Agela) for preparative separations.
• Luna 10 µm-PREP C18(3) column, 250 x 10 mm (Phenomenex).
• Agilent 1100 Series LC system for analytical purity testing.
• Luna 5 µm C18(2) analytical column, 250 x 4.6 mm (Phenomenex).
• UV detection at 220 nm for both preparative and analytical assays.

Key results and discussion

• Molecular identity: tirzepatide has high molecular mass consistent with a large therapeutic peptide (approx. 4813 Da; empirical formula C225H348N48O68), which necessitates careful RP-HPLC conditions for adequate retention and separation from related peptide impurities.
• Chromatographic performance: preparative separations allowed collection of discrete fractions containing the major tirzepatide component. Analytical re-injection of collected fractions showed a dominant tirzepatide peak at ~20.7 min on the analytical C18(2) column, with multiple smaller impurity peaks distributed across the chromatogram.
• Purity assessment: the analytical profiles indicated that the main fraction contains the majority of total chromatographic area, demonstrating effective enrichment of tirzepatide. Low-level impurities remained detectable across several retention windows, highlighting the need for iterative purification or orthogonal polishing steps if higher purity or regulatory-grade material is required.
• Chromatographic parameters: tailing factors and USP resolution values reported for individual peaks suggest acceptable peak shape for preparative collection, while the choice of mobile-phase additives differed between preparative (ammonium acetate) and analytical (TFA) methods, reflecting trade-offs between MS-compatibility and optimal peak shape.

Benefits and practical applications of the method

• Scalability: the use of a preparative 10 mm i.d. column and Octopus Plus system provides a straightforward route to scale crude peptide purification from milligram to gram quantities with reproducible fractionation.
• Compatibility with downstream analysis: ammonium acetate-based preparative mobile phase is more compatible with LC–MS if mass confirmation or impurity identification is required, while TFA in analytical runs can improve peak shape for UV-based purity checks.
• Rapid implementation: the described sample preparation and chromatographic conditions are practical for laboratories involved in peptide synthesis and process development, offering a near-term solution to isolate tirzepatide from common synthetic by-products.

Future trends and potential applications

• MS-guided fraction characterization: integrating preparative runs with LC–MS or fraction screening would accelerate identification of sequence-related impurities and guide targeted polishing steps.
• Modifier optimisation: shifting analytical methods toward MS-friendly buffers (e.g., volatile formic or ammonium formate) could simplify impurity characterization while retaining acceptable chromatographic performance.
• High-efficiency stationary phases: adopting sub-2 µm or superficially porous particles in analytical method development can reduce analysis time and improve resolution of closely eluting peptide variants.
• Process scale-up and continuous purification: for larger production demands, transitioning to semi-preparative or preparative columns with higher loading capacity and implementing automated fraction pooling can increase throughput while maintaining purity standards.
• Regulatory and QC integration: translating this workflow into a validated QC method will require robustness testing, system suitability criteria for peptide peak shape and retention, and control strategies for residual impurities.

Conclusion

The presented preparative and analytical HPLC workflow provides a pragmatic approach to enrich and verify tirzepatide purified from crude material. The combination of a Luna 10 µm preparative C18 column with an Octopus Plus system and subsequent analytical confirmation on a Luna 5 µm C18 column and Agilent 1100 gives reproducible separation and clear identification of the main peptide and multiple low-level impurities. For applications requiring higher purity or regulatory compliance, complementary polishing steps and MS-based impurity profiling are recommended.

Reference

• Liu W., Wu L., Tackett B. Tirzepatide Preparation and Purification. Phenomenex application note AN-1179 (2024).